Editas Historical Balance Sheet
EDIT Stock | USD 2.38 0.06 2.46% |
Trend analysis of Editas Medicine balance sheet accounts such as Other Current Liabilities of 23.5 M or Total Current Liabilities of 40.9 M provides information on Editas Medicine's total assets, liabilities, and equity, which is the actual value of Editas Medicine to its prevalent stockholders. By breaking down trends over time using Editas Medicine balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Editas Medicine latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Editas Medicine is a good buy for the upcoming year.
Editas Medicine Inventory |
|
Editas |
About Editas Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Editas Medicine at a specified time, usually calculated after every quarter, six months, or one year. Editas Medicine Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Editas Medicine and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Editas currently owns. An asset can also be divided into two categories, current and non-current.
Editas Medicine Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Editas Medicine assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Editas Medicine books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Editas Medicine balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Editas Medicine are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Editas Medicine's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Editas Medicine current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.At this time, Editas Medicine's Accumulated Other Comprehensive Income is comparatively stable compared to the past year. Property Plant Equipment is likely to gain to about 23.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 26.4M | 43.9M | 36.5M | 36.1M | Total Assets | 677.5M | 514.3M | 499.2M | 395.9M |
Editas Medicine balance sheet Correlations
Click cells to compare fundamentals
Editas Medicine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Editas Medicine balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 508.9M | 572.6M | 677.5M | 514.3M | 499.2M | 395.9M | |
Short Long Term Debt Total | 29.1M | 26.1M | 26.4M | 43.9M | 36.5M | 36.1M | |
Other Current Liab | 24.8M | 17.2M | 9.9M | 20.2M | 22.4M | 23.5M | |
Total Current Liabilities | 60.0M | 58.2M | 46.9M | 60.1M | 63.2M | 40.9M | |
Total Stockholder Equity | 262.4M | 393.6M | 553.6M | 360.7M | 349.1M | 239.8M | |
Other Liab | 163.2M | 101.5M | 60.9M | 60.7M | 69.8M | 71.4M | |
Property Plant And Equipment Net | 39.6M | 39.1M | 43.3M | 59.2M | 45.7M | 35.0M | |
Net Debt | (209.1M) | (113.5M) | (177.1M) | (97.6M) | (87.1M) | (91.5M) | |
Retained Earnings | (549.2M) | (665.2M) | (857.7M) | (1.1B) | (1.2B) | (1.2B) | |
Accounts Payable | 5.8M | 6.4M | 5.1M | 9.5M | 8.3M | 5.3M | |
Cash | 238.2M | 139.7M | 203.5M | 141.5M | 123.7M | 146.9M | |
Non Current Assets Total | 45.0M | 153.5M | 170.2M | 157.6M | 158.3M | 82.0M | |
Non Currrent Assets Other | 107K | 4.7M | 6.8M | 5.3M | 4.7M | 3.3M | |
Other Assets | 1.7M | 4.7M | 6.8M | 5.3M | 6.0M | 6.3M | |
Cash And Short Term Investments | 457.1M | 511.8M | 619.9M | 437.4M | 323.1M | 338.9M | |
Common Stock Shares Outstanding | 50.0M | 58.6M | 67.6M | 68.7M | 76.0M | 49.3M | |
Liabilities And Stockholders Equity | 508.9M | 572.6M | 677.5M | 514.3M | 499.2M | 395.9M | |
Non Current Liabilities Total | 186.5M | 120.8M | 77.0M | 93.5M | 86.8M | 115.2M | |
Other Current Assets | 6.3M | 21.9M | 14.4M | 7.3M | 7.5M | 6.1M | |
Other Stockholder Equity | 811.5M | 1.1B | 1.4B | 1.4B | 1.6B | 1.7B | |
Total Liab | 246.4M | 179.0M | 123.8M | 153.6M | 150.1M | 156.1M | |
Property Plant And Equipment Gross | 39.6M | 39.1M | 58.8M | 80.7M | 72.0M | 41.4M | |
Total Current Assets | 463.8M | 419.1M | 507.3M | 356.8M | 340.8M | 314.0M | |
Accumulated Other Comprehensive Income | 107K | (46K) | (493K) | (3.6M) | 198K | 207.9K | |
Property Plant Equipment | 39.6M | 14.0M | 17.1M | 15.6M | 17.9M | 23.1M | |
Net Tangible Assets | 262.4M | 393.6M | 553.6M | 360.7M | 414.8M | 250.7M | |
Current Deferred Revenue | 23.5M | 20.9M | 11.3M | 8.2M | 9.5M | 14.2M | |
Net Receivables | 418K | 6.0M | 267K | 5.1M | 10.2M | 10.7M | |
Short Term Debt | 5.8M | 13.6M | 20.6M | 22.2M | 24.3M | 14.0M | |
Short Term Investments | 219.0M | 262.4M | 296.3M | 202.8M | 199.5M | 195.2M | |
Capital Surpluse | 811.5M | 1.1B | 1.4B | 1.4B | 1.7B | 854.8M | |
Retained Earnings Total Equity | (549.2M) | (665.2M) | (857.7M) | (1.1B) | (970.3M) | (921.8M) | |
Capital Lease Obligations | 29.1M | 26.1M | 26.4M | 43.9M | 36.5M | 36.2M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.